1. Medtech Insight
  2. >>Geography
  3. >>Europe

Medtech Industry Weighs In On EMA’s AI Regulation Proposals

 
• By Eliza Slawther

Alignment with other relevant regulations, including medtech, should be a main priority for the European Medicines Agency when developing guidance on the use of artificial intelligence, according to MedTech Europe’s director for international affairs.

The European Medicines Agency's building in Amsterdam
• Source: Alamy

Many of the comments that the European Medicines Agency (EMA) has received so far on its July draft reflection paper that set out its proposed strategy for governing the use of AI in the medicinal product lifecycle relate to the interplay between medical devices and medicines.

Joerg Zinserling, an EMA representative from Germany’s Federal Institute for Drugs and Medical Devices (BfArM), made the announcement at a recent two-day workshop held jointly by the EMA and the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.